Liraglutide linked to acute pancreatitis in an obese Indian female, prompting safety review.
Background
The GLP-1 receptor agonist class, including liraglutide, is widely used for type 2 diabetes and obesity management due to its efficacy in glycemic control and weight reduction. While generally well-tolerated, concerns about potential pancreatic adverse events, specifically pancreatitis, have been raised in post-marketing surveillance and some clinical trials. The exact mechanism linking GLP-1R agonists to pancreatitis is not fully understood, but hypotheses include increased pancreatic enzyme secretion or direct effects on pancreatic duct cells. This case report contributes to the understanding of this rare but serious adverse effect, particularly within specific patient demographics.
Study Design
This publication presents a case report detailing the clinical course of an obese Indian female who developed acute pancreatitis following the initiation of liraglutide therapy. The study describes the patient's demographic profile, medical history, presenting symptoms, diagnostic workup including laboratory findings and imaging results, and the subsequent management of her condition. The authors also conducted a review of the literature to contextualize this case within existing evidence regarding liraglutide-induced pancreatitis.
Results
The case report describes an obese Indian female who developed acute pancreatitis after starting liraglutide. The diagnosis was established based on clinical presentation, elevated pancreatic enzymes (likely amylase and lipase, though specific numbers are not provided in the abstract), and characteristic imaging findings. Upon discontinuation of liraglutide, the patient's symptoms resolved, and her pancreatic enzyme levels normalized. The literature review identified other documented cases of liraglutide-associated pancreatitis, reinforcing the potential, albeit rare, for this adverse event. The report suggests a temporal relationship between liraglutide exposure and the onset of pancreatitis in this patient. Specific details on the liraglutide dose or duration of use before onset are not available in the abstract.
Key Findings
- An obese Indian female developed acute pancreatitis after initiating liraglutide therapy.
- Pancreatitis resolved upon discontinuation of liraglutide.
- The case contributes to the documented instances of liraglutide-associated pancreatitis.
Why It Matters
Clinicians and individuals using liraglutide should be aware of the rare but serious risk of acute pancreatitis, especially in populations with pre-existing risk factors for pancreatic disease or specific genetic predispositions. This case report adds to the growing body of evidence supporting careful patient selection and monitoring for symptoms like severe abdominal pain, which could indicate pancreatitis. While liraglutide remains a valuable tool for obesity and type 2 diabetes, this highlights the importance of patient education on potential adverse effects and the need for prompt medical evaluation if symptoms arise. It underscores that even established medications can have rare, significant side effects that warrant continued vigilance.
liraglutide
pancreatitis
obesity
case-report
adverse-event
glp-1-agonist